Octanoate, Octanoic Acid.
Caprylic acid is a medium-chain fatty acid that is found in palm oil, coconut oil, and the milk of humans and bovines.
Caprylic acid is taken by mouth for epilepsy (seizures), low levels of the blood protein albumin in people undergoing dialysis, digestive disorders such as dysbiosis (abnormal levels of bacteria in the stomach), abnormal absorption of fats, and chylothorax (leakage of a substance called chyle into the chest cavity).
When taken as part of a ketogenic or medium-chain triglyceride (MCT) diet, caprylic acid seems to help reduce the number of seizures in people with epilepsy. However, side effects and difficulty following the diet seem to limit its long-term use. More evidence is needed to rate caprylic acid for this use.
How does work?
Caprylic acid might lower blood pressure in some people. It can also be given to people as part of a test used to measure gastric emptying.
Insufficient Evidence to Rate Effectiveness for...
- Epilepsy (seizures) When taken as part of a ketogenic or medium-chain triglyceride (MCT) diet, caprylic acid seems to help reduce the number of seizures in people with epilepsy. However, side effects and difficulty following the diet seem to limit its long-term use.
- Low blood levels of albumin (hypoalbuminemia) in people undergoing dialysis.
- Digestive disorders.
- Abnormal absorption of fats (lipid malabsorption).
- Reducing the leakage of a substance called chyle into the chest cavity (chylothorax).
- Other conditions. .
QUESTION
See AnswerCaprylic acid is LIKELY SAFE for most people when taken by mouth in food amounts or when used at approved doses for nutritional supplementation and in tests to measure stomach emptying. It can cause some side effects, including nausea, bloating, and diarrhea.
Caprylic acid is POSSIBLY SAFE when taken by mouth as part of a ketogenic diet or a diet high in medium chain triglycerides (MCTs) under the guidance of a physician. However, diets containing high amounts of caprylic acid might cause constipation, vomiting, stomach pain, low levels of calcium in the blood, drowsiness, or growth problems.
Caprylic acid is LIKELY UNSAFE when taken by mouth by people with a condition known as medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. People with this condition are not able to break down caprylic acid appropriately. This can lead to increased levels of caprylic acid in the blood, which may increase the risk of comas.
Pregnancy and breast-feeding: Not enough is known about the use of caprylic acid during pregnancy and breast-feeding. Stay on the safe side and avoid use.Liver disease: Caprylic acid is broken down by the liver. There is some concern that people with liver disease might not be able to break down caprylic acid. This might cause blood levels of caprylic acid to increase. However, other research suggests that people with liver disease are still able to break down caprylic acid. Until more is known, use with caution.
Low blood pressure (hypotension): Caprylic acid can lower blood pressure. In theory, caprylic acid might cause blood pressure to go too low if used by people prone to low blood pressure. Use with caution. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: People with MCAD deficiency are not able to break down caprylic acid appropriately. This can lead to increased levels of caprylic acid in the blood, which might increase the risk of comas. Avoid using.
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: People with MCAD deficiency are not able to break down caprylic acid appropriately. This can lead to increased levels of caprylic acid in the blood, which might increase the risk of comas. Avoid using.
Medications for high blood pressure (Antihypertensive drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Caprylic acid might lower blood pressure. Taking caprylic acid along with medications for high blood pressure might cause your blood pressure to go too low.
Some medications for high blood pressure include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), amlodipine (Norvasc), hydrochlorothiazide (HydroDIURIL), furosemide (Lasix), and many others.
NSAIDs (Nonsteroidal anti-inflammatory drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to reduce pain and swelling. In the blood, NSAIDs bind to a protein called albumin. When bound to albumin, NSAIDs are not active. When displaced from albumin, NSAIDs are active. Caprylic acid can also bind to albumin. Taking caprylic acid along with NSAIDs might displace NSAIDs from albumin, increasing the amount that is active. This might increase the effects and side effects of NSAIDs.
Some NSAIDs include ibuprofen (Advil, Motrin, Nuprin, others), indomethacin (Indocin), naproxen (Aleve, Anaprox, Naprelan, Naprosyn), piroxicam (Feldene), aspirin, and others.
Warfarin (Coumadin)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
In the blood, warfarin (Coumadin) binds to a protein called albumin. When bound to albumin, warfarin is not active. When displaced from albumin, warfarin (Coumadin) slows blood clotting. Like warfarin, caprylic acid binds to albumin. Taking caprylic acid along with warfarin might displace warfarin from albumin. This might increase the effects of warfarin and increase the chances of bruising and bleeding. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.
The following doses have been studied in scientific research:
BY MOUTH:
- For evaluating gastric emptying: 100 mg of caprylic acid has been added to 40 grams of oil or to a solid meal and taken prior to testing.
SLIDESHOW
See SlideshowNatural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Audran R, Pejaudier L, Steinbuch M. [Preparation of immunoglobulins G,A,M (IgGAM) for therapeutic use. Conditions for enrichment in IgA or in IgM]. Rev Fr Transfus Immunohematol 1975;18(2):119-35. View abstract.
Blatrix C, Thebault J, Steinbuch M. [Properties of and information about a new preparation of immunoglobulins (IgGAM) enriched in IgA and IgM]. Rev Fr Transfus Immunohematol 1977;20(3):419-26. View abstract.
Cappello G, Malatesta MG, Ferri A, et al. Gastric emptying of a solid-liquid meal measured with 13C octanoic acid breath test and real-time ultrasonography: a comparative study. Am J Gastroenterol 2000;95(11):3097-3100. View abstract.
Charbrol B, Mancini J, Bertrand C, et al. [Generalized epilepsy disclosing medium-chain-acyl-CoA dehydrogenase deficiency]. Arch Fr Pediatr 1993;50(6):497-500. View abstract.
Duran M, Mitchell G, de Klerk JB, et al. Octanoic acidemia and octanoylcarnitine excretion with dicarboxylic aciduria due to defective oxidation of medium-chain fatty acids. J Pediatr 1985;107(3):397-404. View abstract.
Duran, M., Mitchell, G., de Klerk, J. B., de Jager, J. P., Hofkamp, M., Bruinvis, L., Ketting, D., Saudubray, J. M., and Wadman, S. K. Octanoic acidemia and octanoylcarnitine excretion with dicarboxylic aciduria due to defective oxidation of medium-chain fatty acids. J Pediatr 1985;107(3):397-404. View abstract.
Fischer H, Wetzel K. The future of 13C-breath tests. Food Nutr Bull 2002;23(3 Suppl):53-6. View abstract.
Garner CW, Behal FJ. Effect of pH on substrate and inhibitor kinetic constants of human liver alanine aminopeptidase. Evidence for two ionizable active center groups. Biochemistry 1975;14(23):5084-8. View abstract.
Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993;104(6):1640-7. View abstract.
Gregersen N, Rosleff F, Kolvraa S, et al. Non-ketotic C6-C10-dicarboxylic aciduria: biochemical investigations of two cases. Clin Chim Acta 1980;102(2-3):179-89. View abstract.
Han J, Hamilton JA, Kirkland JL, et al. Medium-chain oil reduces fat mass and down-regulates expression of adipogenic genes in rats. Obes Res 2003;11(6):734-44. View abstract.
Hayball PF, Holman JW, Nation RL. Influence of octanoic acid on the reversible protein binding of ketorolac enantiomers to human serum albumin (HSA): comparative liquid chromatographic studies using a HSA chiral stationary phase. J Chromatogr B Biomed Appl 1994;662(1):128-33. View abstract.
Hopkins IJ, Lynch BC. Use of ketogenic diet in epilepsy in childhood. Aust Paediatr J 1970;6:25-9.
Hoshimoto A, Suzuki Y, Katsuno T, et al. Caprylic acid and medium-chain triglycerides inhibit IL-8 gene transcription in Caco-2 cells: comparison with the potent histone deacetylase inhibitor trichostatin A. Br J Pharmacol 2002;136(2):280-6. View abstract.
Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 1971;21(11):1097-1103. View abstract.
Huttenlocher PR. Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr Res 1976;10:536-40. View abstract.
Ikeda I, Tomari Y, Sugano M, et al. Lymphatic absorption of structured glycerolipids containing medium-chain fatty acids and linoleic acid, and their effect on cholesterol absorption in rats. Lipids 1991;26(5):369-73. View abstract.
Janaki S, Rashid MK, Gulati MS, et al. A clinical electroencephalographic correlation of seizures on a ketogenic diet. Indian J Med Res 1976;64:1057-63. View abstract.
Kennedy MJ, Orourke AL, et al. Inhibition of bacterial foodborne pathogens by the lactoperoxidase system in combination with monolaurin. Int J Food Microbiol 2002;73(1):1-9. View abstract.
Kinsman SL, Vining EP, Quaskey SA, et al. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia 1992;33(6):1132-6. View abstract.
Kristev A, Mitkov D, Lukanov Y, Chapkynov P. The effect of octanoic fatty acid on the cardiovascular system of the guinea pig. Cor Vasa 1989;31(4):321-7. View abstract.
Kristev A, Mitkov D, Lukanov Y, Chapkynov P. The effect of octanoic fatty acid on the cardiovascular system of the guinea pig. Cor Vasa 1989;31(4):321-7. View abstract.
Kuhara T, Matsumoto I, Ohno M, Ohura T. Identification and quantification of octanoyl glucuronide in the urine of children who ingested medium-chain triglycerides. Biomed Environ Mass Spectrom 1986;13(11):595-8. View abstract.
Liefaard G, Heineman E, Molenaar JC, Tibboel D. Prospective evaluation of the absorptive capacity of the bowel after major and minor resections in the neonate. J Pediatr Surg 1995;30(3):388-91. View abstract.
Lima TM, Kanunfre CC, Pompeia C, et al. Ranking the toxicity of fatty acids on Jurkat and Raji cells by flow cytometric analysis. Toxicol In Vitro 2002;16(6):741-7. View abstract.
Maes BD, Hiele MI, Geypens BJ, et al. Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline. Gut 1994;35(3):333-7. View abstract.
Massolini G, Aubry AF, McGann A, Wainer IW. Determination of the magnitude and enantioselectivity of ligand binding to rat and rabbit serum albumins using immobilized-protein high performance liquid chromatography stationary phases. Biochem Pharmacol 1993;46(7):1285-93. View abstract.
Nagata J, Kasai M, Negishi S, Saito M. Effects of structured lipids containing eicosapentaenoic or docosahexaenoic acid and caprylic acid on serum and liver lipid profiles in rats. Biofactors 2004;22(1-4):157-60. View abstract.
Nair MK, Joy J, Venkitanarayanan KS. Inactivation of Enterobacter sakazakii in reconstituted infant formula by monocaprylin. J Food Prot 2004;67(12):2815-9. View abstract.
Neuhauser I. Successful treatment of intestinal moniliasis with fatty acid-resin complex. AMA Arch Intern Med 1954;93(1):53-60. View abstract.
Noctor TA, Wainer IW, Hage DS. Allosteric and competitive displacement of drugs from human serum albumin by octanoic acid, as revealed by high-performance liquid affinity chromatography, on a human serum albumin-based stationary phase. J Chromatogr 1992;577(2):305-15. View abstract.
Pfaffenbach B, Wegener M, Adamek RJ, et al. [Non-invasive 13C octanoic acid breath test for measuring stomach emptying of a solid test meal--correlation with scintigraphy in diabetic patients and reproducibility in healthy probands]. Z Gastroenterol 1995;33(3):141-5. View abstract.
Rajaian H, Symonds HW, Bowmer CJ. Drug binding sites on chicken albumin: a comparison to human albumin. J Vet Pharmacol Ther 1997;20(6):421-6. View abstract.
Randich A, Spraggins DS, Cox JE, et al. Jejunal or portal vein infusions of lipids increase hepatic vagal afferent activity. Neuroreport 2001;12(14):3101-5. View abstract.
Robertson MD, Jackson KG, Fielding BA, et al. Acute ingestion of a meal rich in n-3 polyunsaturated fatty acids results in rapid gastric emptying in humans. Am J Clin Nutr 2002;76(1):232-8. View abstract.
Robinson MK, Whittle E, Basketter DA. A two-center study of the development of acute irritation responses to fatty acids. Am J Contact Dermat 1999;10(3):136-45. View abstract.
Robinson MK. Population differences in acute skin irritation responses. Race, sex, age, sensitive skin and repeat subject comparisons. Contact Dermatitis 2002;46(2):86-93. View abstract.
Samsom M, Vermeijden JR, Smout AJ, et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care 2003;26(11):3116-22. View abstract.
Schneider AR, Kraut C, Lindenthal B, et al. Total body metabolism of 13C-octanoic acid is preserved in patients with non-alcoholic steatohepatitis, but differs between women and men. Eur J Gastroenterol Hepatol 2005;17(11):1181-4. View abstract.
Schonfeld P, Wojtczak AB, Geelen MJ, et al. On the mechanism of the so-called uncoupling effect of medium- and short-chain fatty acids. Biochim Biophys Acta 1988;936(3):280-8. View abstract.
Schwartz RH, Eaton J, Bower BD. Ketogenic diets in the treatment of epilepsy: short-term clinical effects. Dev Med Child Neurol 1989;31:145-51. View abstract.
Sills MA, Forsythe WI, Haidukewych D, et al. The medium chain triglyceride diet and intractable epilepsy. Arch Dis Child 1986;61:1168-72. View abstract.
Sills MA, Forsythe WI, Haidukewych D, et al. The medium chain triglyceride diet and intractable epilepsy. Arch Dis Child 1986;61:1168-72. View abstract.
Sogorb MA, Carrera V, Vilanova E. Hydrolysis of carbaryl by human serum albumin. Arch Toxicol 2004;78(11):629-34. View abstract.
Traul KA, Driedger A, Ingle DL, Nakhasi D. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol 2000;38(1):79-98. View abstract.
Trauner DA. Medium-chain triglyceride (MCT) diet in intractable seizure disorders. Neurology 1985;35:237-8. View abstract.
van de Casteele M, Luypaerts A, Geypens B, et al. Oxidative breakdown of octanoic acid is maintained in patients with cirrhosis despite advanced disease. Neurogastroenterol Motil 2003;15(2):113-20. View abstract.
Van Den Driessche M, Peeters K, Marien P, et al. Gastric emptying in formula-fed and breast-fed infants measured with the 13C-octanoic acid breath test. J Pediatr Gastroenterol Nutr 1999;29(1):46-51. View abstract.
Vining EPG, Freeman JM, Ballaban-Gill K, et al. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol 1998;55:1433-7. View abstract.
Vossen R, Beckeringh TE, Dorland L, Bruinvis L, Wadman SK. Octanoylglucuronide excretion in patients with a defective oxidation of medium-chain fatty acids. Clin Chim Acta 1985 Nov 15;152(3):253-60. View abstract.
Wanten GJ, Janssen FP, Naber AH. Saturated triglycerides and fatty acids activate neutrophils depending on carbon chain-length. Eur J Clin Invest 2002;32(4):285-9. View abstract.
Wheaton TA, Stewart I. The distribution of tyramine, N-methyltyramine, hordenine, octopamine, and synephrine in higher plants. Lloydia 1970;33(2):244-54. View abstract.
Yoshida Y, Singh I, Singh AK, et al. Reye syndrome: rate of oxidation of fatty acids in leukocytes and serum levels of lipid peroxides. J Exp Pathol 1989;4(3):133-9. View abstract.